Carcinoma, Papillary
Recent clinical, regulatory, research and industry developments relating to this disease.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 2 regulatory approvals from EMA on record.
Regulatory UpdatesViewHide
- 2026-05-28Approval — Nadofaragene firadenovecAdstiladrin is indicated as monotherapy for the treatment of adult patients with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumours.
- 2026-02-16Approval — Nogapendekin alfa inbakiceptAnktiva in combination with Bacillus Calmette-Guérin (BCG) is indicated for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumours.
- 2026-05-28RegulatoryApproval — Nadofaragene firadenovecAdstiladrin is indicated as monotherapy for the treatment of adult patients with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumours.
- 2026-02-16RegulatoryApproval — Nogapendekin alfa inbakiceptAnktiva in combination with Bacillus Calmette-Guérin (BCG) is indicated for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumours.
Therapeutic landscape
Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.
Approval — Adstiladrin is indicated as monotherapy for the treatment of adult patients with Bacillus… (2026)
Approval — Anktiva in combination with Bacillus Calmette-Guérin (BCG) is indicated for the treatment… (2026)
Approval — Hepatocellular carcinoma Nexavar is indicated for the treatment of hepatocellular carcino… (2006)
Clinical trials
The current development programme across all trial phases.
Regulatory timeline
Drug regulatory events matched to this condition by indication — EMA.
European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Leading journals2
- JAMA oncology1
- The Journal of clinical endocrinology and metabolism1
Leading researchers8
- Al Ghuzlan A1
- Alves VA1
- Asa SL1
- Baloch ZW1
- Barletta JA1
- Basolo F1
- El-Naggar AK1
- Ghossein RA1
Affiliations (unnormalised)6
- Brigham and Women's Hospital1
- Department of Pathology and Laboratory Medicine1
- Massachusetts Eye and Ear Infirmary1
- Massachusetts General Hospital1
- Memorial Sloan Kettering Cancer Center1
- New York University School of Medicine1
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Reference
Authoritative identity, definition & identifiers.
A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed)
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.